Alzamend Neuro (ALZN)
NASDAQ:ALZN
ALZN Stock Chart & Stats
$2.10
-$0.10(-8.06%)
At close: 4:00 PM EST
$2.10
-$0.10(-8.06%)
Day’s Range― - ―
52-Week Range$0.84 - $3.60
Previous Close$1.15
Volume144.13K
Average Volume (3M)146.22K
Market Cap
$4.36M
Enterprise Value$1.02M
Total Cash (Recent Filing)$2.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,804,741
10 Day Avg. Volume147,464
30 Day Avg. Volume146,221
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.60
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$25.00Price Target Upside1090.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company reported positive Top-line results from the Phase 2 study for AL001, which is a positive development for the stock.
Financial StabilityThe company has enough cash to sustain operations until late-2025, providing financial stability for ongoing research and development activities.
ValuationThe current valuation is considered attractive, with a maintained BUY rating, reflecting a balance between high risks and large upside opportunities.
Bears Say
Financial PositionThe company remains in a challenging financial position (including potential dilution from convertible securities) and will likely require additional capital before it can move into patients.
Alzamend Neuro News
ALZN FAQ
What was Alzamend Neuro’s price range in the past 12 months?
Alzamend Neuro lowest stock price was $0.84 and its highest was $3.60 in the past 12 months.
What is Alzamend Neuro’s market cap?
Alzamend Neuro’s market cap is $4.36M.
When is Alzamend Neuro’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alzamend Neuro’s earnings last quarter?
Currently, no data Available
Is Alzamend Neuro overvalued?
According to Wall Street analysts Alzamend Neuro’s price is currently Undervalued.
Does Alzamend Neuro pay dividends?
Alzamend Neuro does not currently pay dividends.
What is Alzamend Neuro’s EPS estimate?
Alzamend Neuro’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alzamend Neuro have?
Alzamend Neuro has 3,804,741 shares outstanding.
What happened to Alzamend Neuro’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alzamend Neuro?
Currently, no hedge funds are holding shares in ALZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alzamend Neuro
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for neurodegenerative and psychiatric illnesses. Its development pipeline features two key candidates. AL001, currently in Phase II clinical trials, administers a proprietary blend of lithium, proline, and salicylate. This compound is designed to address a broad spectrum of conditions such as Alzheimer's, bipolar disorder, post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and other neurodegenerative or psychiatric conditions. Also in its portfolio is AL002, which has successfully completed its preclinical phase. AL002 represents a cell-based therapeutic vaccine strategy, employing mutant-peptide sensitized cells to restore and enhance a patient's immune system in its fight against Alzheimer's disease. Incorporated in 2016, Alzamend Neuro, Inc. maintains its headquarters in Atlanta, Georgia.
ALZN Stock 12 Month Forecast
Average Price Target
$25.00
▲(1090.48% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Quoin Pharmaceuticals
―
Adial Pharmaceuticals
―
Silo Pharma
―
Calidi Biotherapeutics
―
Ownership Overview
3.36% Insiders
0.95% Mutual Funds
<0.01% Other Institutional Investors
95.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---